162 related articles for article (PubMed ID: 28705838)
21. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.
Muench MO; Heitman JW; Inglis H; Fomin ME; Marschner S; Goodrich RP; Norris PJ; Jackman RP
Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210
[TBL] [Abstract][Full Text] [Related]
22. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.
Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM
Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874
[TBL] [Abstract][Full Text] [Related]
23. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
[TBL] [Abstract][Full Text] [Related]
24. Transfusion of pathogen-reduced platelet components without leukoreduction.
Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
[TBL] [Abstract][Full Text] [Related]
25. Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization.
Bordin JO; Bardossy L; Blajchman MA
Transfusion; 1993 Oct; 33(10):798-801. PubMed ID: 8236419
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of 4 crossmatching methods for predicting the success of platelet transfusion].
Santoso S; Kiefel V; Kühn J; Mueller-Eckhardt G; Mueller-Eckhardt C
Beitr Infusionsther; 1990; 26():153-6. PubMed ID: 1703818
[TBL] [Abstract][Full Text] [Related]
27. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.
Slichter SJ; Bolgiano D; Kao KJ; Kickler TS; McFarland J; McCullough J; Woodson R
Transfus Med Rev; 2011 Apr; 25(2):102-10. PubMed ID: 21345638
[TBL] [Abstract][Full Text] [Related]
28. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: a comparative study.
Kao KJ
Blood; 1992 Dec; 80(11):2931-7. PubMed ID: 1450418
[TBL] [Abstract][Full Text] [Related]
29. Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation.
Rozman P
Transpl Immunol; 2002 Aug; 10(2-3):165-81. PubMed ID: 12216947
[TBL] [Abstract][Full Text] [Related]
30. The challenge of platelet alloimmunization: management and prevention.
Kickler TS
Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
[TBL] [Abstract][Full Text] [Related]
31. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
32. Correction of poor platelet transfusion responses with leukocyte-poor HL-A-matched platelet concentrates.
Herzig RH; Herzig GP; Bull MI; Decter JA; Lohrmann HP; Stout FG; Yankee RA; Graw RG
Blood; 1975 Nov; 46(5):743-50. PubMed ID: 1174708
[TBL] [Abstract][Full Text] [Related]
33. Alloimmune refractoriness to platelet transfusions.
Sandler SG
Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
[TBL] [Abstract][Full Text] [Related]
34. Refractoriness to platelet transfusion after single-donor consecutive platelet transfusions and its relationship to platelet antibodies.
Lee M; Kim BK; Park S; Suh C; Park MH; Cho MJ
J Korean Med Sci; 1988 Dec; 3(4):143-9. PubMed ID: 3267362
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates.
McFarland JG; Anderson AJ; Slichter SJ
Br J Haematol; 1989 Nov; 73(3):380-6. PubMed ID: 2605125
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience with transfusion of leukocyte-poor platelet concentrates prepared by filtration with prostacyclin.
van Prooijen HC; Riemens TI; Akkerman JW
Blood; 1987 Jul; 70(1):243-6. PubMed ID: 3297202
[TBL] [Abstract][Full Text] [Related]
37. Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice.
Couvidou A; Angénieux C; Ruch L; Mangin PH; Gachet C; Maître B
Blood Adv; 2023 Apr; 7(8):1356-1365. PubMed ID: 36490266
[TBL] [Abstract][Full Text] [Related]
38. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases.
Klingemann HG; Self S; Banaji M; Deeg HJ; Doney K; Slichter SJ; Thomas ED; Storb R
Br J Haematol; 1987 May; 66(1):115-21. PubMed ID: 3593647
[TBL] [Abstract][Full Text] [Related]
39. Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial.
Norris PJ; Kaidarova Z; Maiorana E; Milani S; Lebedeva M; Busch MP; Custer B; Rebulla P
Transfusion; 2018 May; 58(5):1210-1217. PubMed ID: 29473173
[TBL] [Abstract][Full Text] [Related]
40. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.
Pavenski K; Freedman J; Semple JW
Tissue Antigens; 2012 Apr; 79(4):237-45. PubMed ID: 22385314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
